Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

229 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Multiple roles for CD4+ T cells in anti-tumor immune responses.
Kennedy R, Celis E. Kennedy R, et al. Among authors: celis e. Immunol Rev. 2008 Apr;222:129-44. doi: 10.1111/j.1600-065X.2008.00616.x. Immunol Rev. 2008. PMID: 18363998 Review.
Characterization of human CD4 helper T cell responses against Aurora kinase A.
Kobayashi H, Azumi M, Hayashi S, Sato K, Aoki N, Kimura S, Kakizaki H, Nagato T, Harabuchi Y, Tateno M, Celis E. Kobayashi H, et al. Among authors: celis e. Cancer Immunol Immunother. 2010 Jul;59(7):1029-39. doi: 10.1007/s00262-010-0826-0. Epub 2010 Feb 25. Cancer Immunol Immunother. 2010. PMID: 20182874
The results show that two peptides (Aurora-A(161-175) and Aurora-A(233-247)) were effective in generating HTL responses that were restricted by more than one MHC class II allele (i.e., promiscuous responses). ...
The results show that two peptides (Aurora-A(161-175) and Aurora-A(233-247)) were effective in generating HTL responses that were restricted …
Peptide epitope identification for tumor-reactive CD4 T cells.
Kobayashi H, Celis E. Kobayashi H, et al. Among authors: celis e. Curr Opin Immunol. 2008 Apr;20(2):221-7. doi: 10.1016/j.coi.2008.04.011. Epub 2008 May 20. Curr Opin Immunol. 2008. PMID: 18499419 Free PMC article. Review.
Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP.
Kobayashi H, Nagato T, Oikawa K, Sato K, Kimura S, Aoki N, Omiya R, Tateno M, Celis E. Kobayashi H, et al. Among authors: celis e. Clin Cancer Res. 2005 May 15;11(10):3869-78. doi: 10.1158/1078-0432.CCR-04-2238. Clin Cancer Res. 2005. PMID: 15897588 Free PMC article.
In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma.
Rodeberg DA, Erskine C, Celis E. Rodeberg DA, et al. Among authors: celis e. J Pediatr Surg. 2007 Aug;42(8):1396-402. doi: 10.1016/j.jpedsurg.2007.03.041. J Pediatr Surg. 2007. PMID: 17706503
Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model.
Kalaaji AN, Lu J, Markovic SN, Celis E, Pittelkow MR. Kalaaji AN, et al. Among authors: celis e. Cytokine. 2010 Mar;49(3):287-93. doi: 10.1016/j.cyto.2009.11.016. Epub 2010 Jan 8. Cytokine. 2010. PMID: 20060741
Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
Melanoma Study Group of the Mayo Clinic Cancer Center, Celis E. Melanoma Study Group of the Mayo Clinic Cancer Center, et al. Among authors: celis e. Cancer. 2007 Jul 1;110(1):203-14. doi: 10.1002/cncr.22744. Cancer. 2007. PMID: 17541944 Clinical Trial.
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.
Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Nava-Parada P, et al. Among authors: celis e. Cancer Res. 2007 Feb 1;67(3):1326-34. doi: 10.1158/0008-5472.CAN-06-3290. Cancer Res. 2007. PMID: 17283170 Free PMC article.
Mice that were vaccinated with this approach remained tumor-free or were able to control spontaneous tumor growth and exhibited long-lasting CTL responses, not only against the immunizing peptide but also against other peptides derived from rat HER-2/neu product (i.e., epi …
Mice that were vaccinated with this approach remained tumor-free or were able to control spontaneous tumor growth and exhibited long-lasting …
T helper lymphocytes rescue CTL from activation-induced cell death.
Kennedy R, Celis E. Kennedy R, et al. Among authors: celis e. J Immunol. 2006 Sep 1;177(5):2862-72. doi: 10.4049/jimmunol.177.5.2862. J Immunol. 2006. PMID: 16920921 Free PMC article.
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN, Suman VJ, Ingle JN, Kaur JS, Pitot HC, Loprinzi CL, Rao RD, Creagan ET, Pittelkow MR, Allred JB, Nevala WK, Celis E. Markovic SN, et al. Among authors: celis e. Am J Clin Oncol. 2006 Aug;29(4):352-60. doi: 10.1097/01.coc.0000217877.78473.a4. Am J Clin Oncol. 2006. PMID: 16891861 Clinical Trial.
229 results
Jump to page
Feedback